SecBot SecBot
8-K ·Filed May 7, 2026

GENB

Generate Biomedicines, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-209899
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Revenue decline and widening losses are the key negatives for a pre-commercial biotech. The $516.6M cash position provides a long runway, but the burn rate is accelerating. Watch for upcoming data readouts from GB-0895 Phase 3 and GB-4362 Phase 1 as potential catalysts. The IPO overhang may still be digesting given the recent March 2 pricing.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.59
T+0 close · May 7, 2026 · via day close
Latest settled
+5.52%
T+60 · $14.34
Vs SPY
+1.69%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $13.59entry
  2. T+1 · 6mo ago +0.52%α −0.31% · $13.66
  3. T+5 · 6mo ago +19.35%α +17.85% · $16.22
  4. T+20 · 6mo ago −5.00%α −8.14% · $12.91
  5. T+60 · 4mo ago +5.52%α +1.69% · $14.34

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and a net loss of $61.7M, wider than the $44.3M loss in Q1 2025. The company ended the quarter with $516.6M in cash after its March IPO, providing runway into H1 2028, but the widening loss and revenue decline are the headline financials for a pre-revenue biotech.

Key Financial Metrics

Revenue
$7.2M
est $4.8M · +50.0% · -18.1% YoY

Key Facts

  • Q1 2026 collaboration revenue $7.2M vs $8.8M in Q1 2025, an 18% YoY decline
  • Net loss widened to $61.7M from $44.3M in the prior-year quarter
  • Cash, cash equivalents, and marketable securities of $516.6M as of March 31, 2026, up from $221.5M at year-end 2025, reflecting $369.3M in net IPO proceeds
  • Cash runway guided into first half of 2028; company expects to require additional capital for long-term operations
  • R&D expenses rose to $57.8M from $46.8M, driven by Phase 3 investment in GB-0895 and personnel costs
  • GB-0895 (anti-TSLP) Phase 3 trials SOLAIRIA-1 and SOLAIRIA-2 in severe asthma are advancing; Phase 1b in COPD ongoing
  • GB-4362 (MMAE neutralizer) received FDA Fast Track designation; first patient dosing expected mid-2026
  • GB-5267 (MUC16 armored CAR T) first patient dosing expected H2 2026 in Phase 1 solid tumor trial

Financial Impact

Revenue declined $1.6M YoY (18%); net loss increased $17.4M (39%); operating cash burn increased to $80.4M from $53.2M

revenuenet lossoperating cash flow

Risk Factors

  • No approved products or recurring revenue stream; entirely dependent on partnership collaboration revenue
  • Accelerating cash burn ($80.4M operating cash outflow in Q1) may require future dilutive financing
  • Phase 3 clinical trial risk for GB-0895; failure would remove the most advanced pipeline asset
  • Competition from established anti-TSLP therapies (e.g., Tezspire) in severe asthma

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-209899
Document: ck0002100782-20260507.htm0001193125-26-209899
Document: 0001193125-26-209899-index-headers.html0001193125-26-209899
Document: 0001193125-26-209899-index.html0001193125-26-209899
Document: 0001193125-26-209899.txt0001193125-26-209899
8-K Data (Synthetic)0001193125-26-209899

Track record

11 reports on GENB

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 5/10 Entry $12.57 Now $10.49 +16.55% settles Dec 11
  2. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
  3. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
  4. Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
  5. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
  7. May 7, 202627w ago 8-K Bearish 6/10 Viewing Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
  8. Mar 2, 202637w ago Insider Cluster Bullish 7/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  9. Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
  10. Feb 27, 202637w ago 424B4 Bearish 7/10 Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026